Edwards Lifesciences (EW) Stock Forecast & Price Target $89.15 -0.94 (-1.05%) Closing price 10/23/2026 03:59 PM EasternExtended Trading$89.16 +0.01 (+0.01%) As of 10/23/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 26 Analyst RatingsSell0Hold7Buy19 Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 7 have given a hold rating, 18 have given a buy rating, and 1 has given a strong buy rating for EW. Consensus Price Target $100.2712.48% Upside According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $100.27. The highest price target for EW is $115.00, while the lowest price target for EW is $85.00. The average price target represents a forecasted upside of 12.48% from the current price of $89.15. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for EW and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy1 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)3 Strong Buy rating(s)Buy18 Buy rating(s)19 Buy rating(s)18 Buy rating(s)12 Buy rating(s)Hold7 Hold rating(s)8 Hold rating(s)8 Hold rating(s)9 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$100.27$100.54$99.96$87.06Forecasted Upside12.48% Upside16.37% Upside20.13% Upside14.33% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy EW Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History EW Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Edwards Lifesciences Stock vs. The CompetitionTypeEdwards LifesciencesHealthcare CompaniesBroader MarketConsensus Rating Score 2.77 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside12.48% Upside1,400.11% Upside16.92% UpsideNews Sentiment RatingPositive NewsSee Recent EW NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/23/2026 Evercore3 of 5 starsVijay Kumar4 of 5 starsReiterated RatingOutperform10/15/2026 Weiss Ratings3 of 5 stars Reiterated RatingHold (C)10/15/2026 Robert W. Baird3 of 5 starsDavid Rescott2 of 5 starsLower TargetNeutral$94.00 ➝ $90.00+1.91%10/8/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsPatrick WoodSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$90.00 ➝ $110.00+32.73%10/7/2026 BarclaysSubscribe to MarketBeat All Access to unlock brokerage rankingsChristopher PasqualeSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeStrong-Buy10/5/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankingsJoanne WuenschSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$96.00 ➝ $101.00+18.50%10/2/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access to unlock brokerage rankingsRobbie MarcusSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$100.00 ➝ $105.00+18.89%9/11/2026 BTIG ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsMarie ThibaultSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$110.00+26.88%8/21/2026 ArgusSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$105.00 ➝ $115.00+30.22%7/27/2026 Rothschild & Co RedburnSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$99.00 ➝ $102.00+15.50% Get the Latest News and Ratings for EW and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. 7/24/2026 Piper SandlerSubscribe to MarketBeat All Access to unlock brokerage rankingsAdam MaederSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight$100.00 ➝ $101.00+20.77%7/24/2026 Sanford C. BernsteinSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetMarket Perform$96.00 ➝ $99.00+12.10%7/24/2026 Jefferies Financial GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$102.00 ➝ $105.00+18.89%7/24/2026 Raymond James FinancialSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetOutperform$100.00 ➝ $103.00+16.63%7/24/2026 Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$100.00 ➝ $103.00+16.63%7/24/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsMike KratkySubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeMarket Perform ➝ Outperform$87.00 ➝ $101.00+20.77%7/21/2026 TD CowenSubscribe to MarketBeat All Access to unlock brokerage rankingsJoshua JenningsSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy$97.00 ➝ $104.00+22.85%7/16/2026 Truist FinancialSubscribe to MarketBeat All Access to unlock brokerage rankingsRichard NewitterSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetHold$90.00 ➝ $95.00+9.28%7/15/2026 MizuhoSubscribe to MarketBeat All Access to unlock brokerage rankingsAnthony PetroneSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$100.00 ➝ $105.00+19.31%7/14/2026 The Goldman Sachs GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Boost TargetBuy$98.00 ➝ $102.00+15.50%7/13/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsShagun SinghSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$100.00 ➝ $110.00+19.09%4/24/2026 Canaccord Genuity GroupSubscribe to MarketBeat All Access to unlock brokerage rankingsWilliam PlovanicSubscribe to MarketBeat All Access to unlock analyst rankingsSet TargetHold$87.00 ➝ $85.00+2.10%4/1/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradePeer Perform ➝ Outperform$92.00+14.91%2/24/2026 Daiwa Securities GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Lower TargetBuy$99.00 ➝ $98.00+11.03%2/11/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsLarry BiegelsenSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$96.00 ➝ $100.00+31.67%1/20/2026 Stifel NicolausSubscribe to MarketBeat All Access to unlock brokerage rankingsRick WiseSubscribe to MarketBeat All Access to unlock analyst rankingsSet TargetBuy$105.00 ➝ $110.00+30.35%10/31/2025 National Bank FinancialSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$92.00+11.54%10/8/2025 OppenheimerSubscribe to MarketBeat All Access to unlock brokerage rankingsSuraj KaliaSubscribe to MarketBeat All Access to unlock analyst rankingsDowngradeOutperform ➝ Market Perform7/25/2025 William BlairSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeStrong-Buy7/15/2025 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsPatrick WoodSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetEqual Weight$75.00 ➝ $81.00+3.39%6/2/2025 Dbs BankSubscribe to MarketBeat All Access to unlock brokerage rankingsN. ChenSubscribe to MarketBeat All Access to unlock analyst rankingsUpgradeHold12/16/2024 Bank of AmericaSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeNeutral ➝ Buy$82.00 ➝ $90.00+20.97%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:03 PM ET. Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com. Edwards Lifesciences Bull Case Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.: Edwards Lifesciences Co. recently secured FDA approval for its PASCAL Precision system for tricuspid valve repair, a development that positions the company as the only supplier in the U.S. offering both repair and replacement transcatheter options for these valves, significantly expanding its addressable market and competitive moat. The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $0.78 which exceeded the consensus estimate of $0.74, while revenue grew 13.6% year-over-year to $1.74 billion, indicating robust demand for its structural heart disease therapies. Wall Street analysts maintain a positive outlook on the stock, with a consensus rating of Moderate Buy and an average price target of $100.27, which suggests approximately 12% upside potential from the current stock price of $89.15. Edwards Lifesciences Co. maintains a strong balance sheet with a debt-to-equity ratio of only 0.06, providing financial stability and flexibility to invest in research and development without the burden of high leverage, which is particularly attractive in the healthcare sector. The stock has shown consistent momentum, crossing above its 200-day moving average in early October 2026, a technical indicator that often signals the start of a sustained uptrend and increased investor confidence in the company's long-term growth trajectory. Edwards Lifesciences Bear Case Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons: The FDA issued a high-risk early alert regarding a recall of specific lots of the company's Commander M delivery systems due to reports of balloons bursting during procedures, which resulted in one patient death and a serious injury, posing significant regulatory and reputational risks. Insider selling activity has been notable, with multiple executives including VP Daniel J. Lippis and VP Donald E. Bobo Jr. selling thousands of shares in recent months, which can signal a lack of confidence from those with the most intimate knowledge of the company's operations. Several institutional investors have reduced their stakes in the company, with Robeco Institutional Asset Management B.V. decreasing its holdings by 13.0% and Investment House LLC cutting its position by 52.3% in the third quarter, suggesting that large funds are taking profits or reassessing their exposure. The company faces potential margin pressure from tariffs and currency headwinds, as noted by recent analyst commentary, which could erode profitability even if revenue growth continues, particularly given its international operations in Europe and Japan. Short interest in the stock has increased, with shares shorted rising to 9.54 million as of September 30, 2026, indicating that a growing number of traders are betting against the stock's price appreciation, which can create downward pressure on the share price. EW Forecast - Frequently Asked Questions What is Edwards Lifesciences' forecast for 2026? According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $100.27, with a high forecast of $115.00 and a low forecast of $85.00. Should I buy or sell Edwards Lifesciences stock right now? 26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 7 hold ratings, 18 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares. Does Edwards Lifesciences's stock price have much upside? According to analysts, Edwards Lifesciences's stock has a predicted upside of 12.48% based on their 12-month stock forecasts. Has Edwards Lifesciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts. What analysts cover Edwards Lifesciences? Edwards Lifesciences has been rated by research analysts at Argus, Barclays, BTIG Research, Citigroup, Evercore, JPMorgan Chase & Co., Robert W. Baird, Rothschild & Co Redburn, UBS Group, and Weiss Ratings in the past 90 days. Do Wall Street analysts like Edwards Lifesciences more than its competitors? Analysts like Edwards Lifesciences more than other "healthcare" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how EW compares to other companies. Stock Forecasts and Research Tools Related Companies HSIC Stock Forecast AMN Stock Forecast ABT Stock Forecast ISRG Stock Forecast MDT Stock Forecast SYK Stock Forecast BSX Stock Forecast BDX Stock Forecast IDXX Stock Forecast RMD Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Edwards Lifesciences RecommendationsEvercoreWall Street ZenRobert W. BairdWeiss RatingsUBS GroupBarclaysCitigroupJPMorgan Chase & Co.BTIG ResearchArgusRothschild & Co RedburnPiper SandlerJefferies Financial GroupLeerink PartnersSanford C. Bernstein MarketBeat monitors more than a dozen sources for Edwards Lifesciences analyst ratings, with the most recent rating issued on 10/23/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.